U.S. Markets closed

Innovent Biologics, Inc. (1801.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
40.900-0.450 (-1.09%)
At close: 04:08PM HKT

Innovent Biologics, Inc.

168 Dongping Street
Suzhou Industrial Park
Suzhou 215123
86 512 6956 6088

Full Time Employees4,596

Key Executives

NameTitlePayExercisedYear Born
Dr. De-Chao Yu Ph.D.Chairman & CEON/AN/A1964
Dr. Yong Jun Liu M.D., Ph.D.PresN/AN/A1969
Mr. Hao Xi EdeCFO & Exec. DirectorN/AN/A1959
Dr. Changshou GaoSr. VP & CTON/AN/AN/A
Ms. Vivian ZhangChief People OfficerN/AN/AN/A
Mr. Min LiuChief Commercial OfficerN/AN/AN/A
Mr. Dongming WangSr. VP of QualityN/AN/AN/A
Ms. Yanju WangJoint Company Sec.N/AN/A1989
Ms. Lok Yee Chan A.C.I.S., A.C.S.Joint Company Sec.N/AN/A1991
Ms. Linda M. PullanVP of Bus. Devel.N/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-303, an adalimumab biosimilar for autoimmune diseases; and IBI-305, a bevacizumab biosimilar to treat metastatic colorectal cancer and non-small cell lung cancer. In addition, it develops IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-308, a human monoclonal antibody for lung, esophageal, and gastric cancer, as well as Hodgkin's lymphoma; and IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further, the company develops IBI-101, an anti-OX40 agonistic antibody for advanced solid tumors; and IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with The University of Texas MD Anderson Cancer Center to co-develop TYVYT, a sintilimab injection; Roche Group for the discovery and development of bispecific antibodies and multiple cell therapies; Ascentage Pharma for joint commercialization of Olverembatinib; NeoCura Bio-Medical Technology Co. Ltd. to study the combination therapy of Sintilimab and neoantigen vaccine NEO_PLIN2101 for cancer treatment; and Eli Lilly and Company, and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Corporate Governance

Innovent Biologics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.